List of Tolsura drug patents

Tolsura is owned by Mayne Pharma Intl.

Tolsura contains Itraconazole.

Tolsura has a total of 6 drug patents out of which 0 drug patents have expired.

Tolsura was authorised for market use on 11 December, 2018.

Tolsura is available in capsule;oral dosage forms.

Tolsura can be used as treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis.

The generics of Tolsura are possible to be released after 21 June, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8771739 MAYNE PHARMA INTL Pharmaceutical compositions for poorly soluble drugs
Jul, 2023

(5 months from now)

US10806792 MAYNE PHARMA INTL Itraconazole compositions and dosage forms, and methods of using the same
Jun, 2033

(10 years from now)

US8921374 MAYNE PHARMA INTL Itraconazole compositions and dosage forms, and methods of using the same
Jun, 2033

(10 years from now)

US10463740 MAYNE PHARMA INTL Itraconazole compositions and dosage forms, and methods of using the same
Jun, 2033

(10 years from now)

US9272046 MAYNE PHARMA INTL Itraconazole compositions and dosage forms, and methods of using the same
Jun, 2033

(10 years from now)

US9713642 MAYNE PHARMA INTL Itraconazole compositions and dosage forms, and methods of using the same
Jun, 2033

(10 years from now)

Drugs and Companies using ITRACONAZOLE ingredient

Market Authorisation Date: 11 December, 2018

Treatment: Treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic